Aptevo Therapeutics (APVO) vs Decoy Therapeutics (DCOY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Decoy Therapeutics is the larger company by market cap ($3.5 million vs $3.2 million), about 1.1 times the size. On valuation, Aptevo Therapeutics trades at a lower trailing P/E (0.0x vs 0.1x for Decoy Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APVO | DCOY |
|---|---|---|
| Share price | $1.79 | $1.47 |
| Market cap | $3.24M | $3.51M |
| 1-day change | -0.56% | -3.29% |
| P/E ratio (TTM) | 0.03 | 0.12 |
| EPS (TTM) | $66.96 | $12.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.14 | $55.92 |
| 52-week low | $1.37 | $1.46 |
| Distance from 52-week high | -94.25% | -97.37% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1324.58% | +104.08% |
| Average volume | 91.51K | 2.17M |
| Shares outstanding | 1.81M | 2.39M |
| Employees | 33 | 11 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Decoy Therapeutics trades at a higher earnings multiple (0.1x vs 0.0x trailing P/E).
About Aptevo Therapeutics
APVO stock →Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Decoy Therapeutics
DCOY stock →Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
APVO vs DCOY FAQ
Which is bigger, Aptevo Therapeutics or Decoy Therapeutics?
Decoy Therapeutics (DCOY) is larger, with a market capitalization of $3.51M compared with $3.24M for Aptevo Therapeutics (APVO).
Which has the lower P/E ratio, APVO or DCOY?
APVO has the lower trailing P/E at 0.0, versus 0.1 for DCOY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Aptevo Therapeutics and Decoy Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.